Filing Flows › Teva Pharmaceutical Industries (TEVA) › Guidance history
Teva Pharmaceutical Industries (TEVA) guidance history: what it guided and what it reported
Teva Pharmaceutical Industries gave guidance in 12 earnings releases on file since Jan 31, 2024. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +0.9% against the guided midpoint. Its releases raised guidance 7 times and lowered it twice.
Revenue
Met or beat 1 of 1 periods (0 above, 1 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $16.4B–$16.8B (Apr 29, 2026) | — | to be reported | — |
| FY2025 | $16.8B–$17.4B (Jan 29, 2025) | $17.3B | within the range | +0.9% |
Adjusted operating income
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $3.8B–$4.0B (Apr 29, 2026) → reaffirmed $3.8B–$4.0B (Jul 29, 2026) | — | to be reported | — |
Tax rate
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 16.0%–19.0% (Jan 28, 2026) | — | to be reported | — |
| FY2025 | 15.0%–18.0% (Jan 29, 2025) | — | — | — |
| FY2024 | 14.0%–17.0% (Jan 31, 2024) | — | — | — |
Adjusted tax rate
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 20.0%–23.0% (Apr 29, 2026) → reaffirmed 20.0%–23.0% (Jul 29, 2026) → reaffirmed 20.0%–23.0% (Nov 3, 2026) | — | to be reported | — |
| FY2025 | 15.0%–18.0% (May 7, 2025) → reaffirmed 15.0%–18.0% (Jul 30, 2025) → reaffirmed 15.0%–18.0% (Nov 5, 2025) | — | — | — |
| FY2024 | 14.0%–17.0% (May 8, 2024) → reaffirmed 14.0%–17.0% (Nov 6, 2024) | — | — | — |
EPS
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $2.57–$2.77 (Jan 28, 2026) → raised $750.00–$790.00 (Apr 29, 2026) → lowered $1.91–$2.11 (Jul 29, 2026) → lowered $0.07 (Nov 3, 2026) | — | to be reported | — |
| FY2025 | $600.00 (Jan 29, 2025) → lowered $2.35–$2.65 (May 7, 2025) → raised $600.00 (Jul 30, 2025) | — | — | — |
| FY2024 | $2.20–$2.50 (Jan 31, 2024) | — | — | — |
Free cash flow
The GAAP figure from the filings is shown for each period reported; it is not judged against the guide, which may leave items out (one-off payments, acquisitions).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2024 | $1.7B–$2.0B (May 8, 2024) | $749M (GAAP) | not judged | — |
The latest quarter
Teva Pharmaceutical Industries, Q3 2026: revenue $4.4B (-2% year over year), operating margin 16.2%, net earnings $234M, operating cash flow $241M. The chart follows the revenue to costs, profit and cash.
Questions
Does Teva Pharmaceutical Industries beat its guidance?
Teva Pharmaceutical Industries gave guidance in 12 earnings releases on file since Jan 31, 2024. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +0.9% against the guided midpoint.
How often does Teva Pharmaceutical Industries raise guidance?
Its earnings releases raised guidance 7 times and lowered it twice since Jan 31, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.